Views

CrossRef citations to date

Altmetric

Letters to the Editor

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz LudwigWilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Correspondence[email protected]

Meletios A. DimopoulosSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece;

Philippe MoreauUniversity of Nantes, Nantes, France;

Wee-Joo ChngNational University Cancer Institute, Singapore; ;National University Health System, Singapore; ;Cancer Science Institute, Singapore; ;National University of Singapore, Singapore;

Hartmut GoldschmidtHeidelberg Medical University, Heidelberg, Germany;

Roman HájekUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;

Thierry FaconCHRU Lille Hôpital Claude Huriez, Lille, France;

Ludek PourUniversity Hospital Brno, Brno, Czech Republic;

Ruben NiesvizkyWeill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA;

Albert OriolInstitut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;

Laura RosiñolHospital Clínic de Barcelona, Barcelona, Spain;

Aleksandr SuvorovFirst Republican Clinical Hospital of Udmurtia, Izhevsk, Russia;

Gianluca GaidanoDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy;

Tomas PikaUniversity Hospital Olomouc, Olomouc, Czech Republic;

Katja WeiselUniversitatsklinikum Tubingen, Tubingen, Germany;

Vesselina Goranova-MarinovaUniversity Multiprofile Hospital for Active Treatment “Sv. Georgi” and Medical University, Plovdiv, Bulgaria;

Antonio PalumboUniversity of Torino, Torino, Italy;

Heidi H. GillenwaterOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Nehal MohamedOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Sanjay AggarwalOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Shibao FengOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;

Douglas JoshuaRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia

show all

Click to increase image sizeClick to decrease image size

Acknowledgments

The ENDEAVOR study was supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. The authors would like to thank Jesse Potash of Amgen Inc. for medical writing assistance.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2017.1298755.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Information for

Open access

Opportunities

Help and information

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Acknowledgments

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature